Investigational drug · Phase 3
KYV-101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
13
Any phase or sponsor naming "KYV-101"
First trial start
2024
Aug 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KYV-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis
- MS
- Myasthenia Gravis
- Generalized Myasthenia Gravis
Approved drugs for the same conditions: Multiple sclerosis · Myasthenia gravis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "KYV-101" as an intervention, largest first.
- KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple SclerosisPivotal-lookingActive, not recruiting
Kyverna TherapeuticsIndustry
NCT06384976 · 120 participants (planned) · Start Sep 20, 2024 · Primary completion Apr 2027
Drug: KYV-101; Standard lymphodepletion regimen and 1 more · For: Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive; Multiple Sclerosis and 1 more
Sites: Palo Alto, California
Kyverna TherapeuticsIndustry
NCT07403188 · 70 participants (planned) · Start Nov 24, 2025 · Primary completion Jan 2041
Drug: KYV-101 · For: Refractory Lupus Nephritis; Myasthaenia Gravis; Stiff Person Syndrome and 4 more
Sites: Denver, Colorado
- KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia GravisPivotal-lookingRecruiting
Kyverna TherapeuticsIndustry
NCT06193889 · 66 participants (planned) · Start Aug 28, 2024 · Primary completion Sep 2027
Drug: Standard of Care Treatment; Standard lymphodepletion regimen and 1 more · For: Myasthenia Gravis; Generalized Myasthenia Gravis
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 22 sites in all
Kyverna TherapeuticsIndustry
NCT06588491 · 27 participants · Start Sep 25, 2024 · Primary completion Jun 25, 2026
Drug: Standard lymphodepletion regimen · For: Stiff-Person Syndrome; SPS
Sites: Aurora, Colorado; Rochester, Minnesota; Philadelphia, Pennsylvania
- CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101Active, not recruiting
David PorterAcademic, hospital or other
NCT06152172 · 24 participants (planned) · Start Aug 5, 2024 · Primary completion Feb 2027
Drug: KYV-101; Cyclophosphamide and 1 more · For: Idiopathic Inflammatory Myopathies; Diffuse Cutaneous Systemic Sclerosis; SLE Nephritis and 1 more
Sites: Philadelphia, Pennsylvania
- Study of KYV-101 Anti-CD19 CAR T Therapy in Adult DermatomyositisActive, not recruiting
Stanford UniversityAcademic, hospital or other
NCT06298019 · 21 participants (planned) · Start Aug 2, 2024 · Primary completion Jun 2027
Drug: KYV-101 · For: Dermatomyositis
Sites: Palo Alto, California; Stanford, California
- Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisActive, not recruiting
Charite University, Berlin, GermanyAcademic, hospital or other
NCT06475495 · 13 participants (planned) · Start Dec 4, 2024 · Primary completion Jun 2027
Drug: KYV101; Rituximab (active comparator) · For: Rheumatoid Arthritis
Sites: Berlin, Germany
Stanford UniversityAcademic, hospital or other
NCT06138132 · 12 participants (planned) · Start Apr 10, 2024 · Primary completion Jun 2027
Drug: KYV-101 anti-CD19 CAR-T cell therapy; Standard lymphodepletion regimen · For: Multiple Sclerosis; Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive
Sites: Palo Alto, California
- A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple SclerosisActive, not recruiting
Bruce CreeAcademic, hospital or other
NCT06451159 · 10 participants (planned) · Start Jun 20, 2024 · Primary completion Feb 1, 2026
Drug: KYV-101 (Biological) - 0.33 ×10^8 cells; KYV-101 (Biological) - 1 ×10^8 cells and 2 more · For: Progressive Multiple Sclerosis
Sites: San Francisco, California
- Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA VasculitisNot yet recruiting
David SimonAcademic, hospital or other
NCT06590545 · 8 participants (planned) · Start Jan 2025 · Primary completion Jan 2027
Drug: KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy · For: ANCA-IgG-positive ANCA Associated Vasculitis
Newest research
PubMed records naming it or its code names, newest first.
- Neutrophil transcriptomics in SLE reveals intrinsic disease signatures, shared ex vivo adaptation, and transcriptional reset after CAR T-cell therapy.
Dehdashtian E, Hu G, Whiteman L, et al. · Ann Rheum Dis 2026
- A new therapeutic frontier: CD19-targeting CAR-T cell therapy in rheumatoid arthritis: a concise report.
Kremer P, Haase I, Richter J, et al. · Rheumatology (Oxford) 2026
- CAR-engineered cell therapies: current understandings and future perspectives.
Bayat M, Nahand JS · Mol Biomed 2026
- CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.
Ortuño-Sahagún D, Hermosillo-Abundis C, Reyes-Mata MP, et al. · Mult Scler Relat Disord 2025
- Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis.
Gerber JM, Dehdashtian E, Hu G, et al. · Lupus Sci Med 2025
- Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis.
Ayzenberg I, Aloizou AM, Lohmann C, et al. · Neurol Neuroimmunol Neuroinflamm 2025
Also in development for Multiple Sclerosis, Primary Progressive
- FenebrutinibRO7010939, GDC-0853Phase 36 trials
Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.